Healthcare Industry News:  sanofi-aventis 

Biopharmaceuticals Devices Oncology

 News Release - May 27, 2008

Nanomedicine Company Nanobiotix Elects Former Sanofi-Aventis Oncology Researcher Elsa Borghi, MD, as its Medical Director

PARIS--(HSMN NewsFeed)--Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that it has appointed Elsa Borghi, MD, as medical director.

Previously, Dr. Borghi worked in the R&D oncology department for sanofi-aventis, one of the five largest pharmaceutical companies in the world, until the onset of 2008, when she joined Nanobiotix. She has lead successful clinical trials worldwide for major drugs and registration in the Oncology field. Dr. Borghi began working in the pharmaceutical industry in 1996 on drug safety and international reporting, mainly for oncology and cardiovascular drugs. She began working on pivotal cancer clinical trials in 1999, including early colon cancer, early- and late-stage breast cancer, and prostate cancer, for which she was responsible for a chemotherapy product registration. In addition, Dr. Borghi has worked on soft tissue sarcoma, lung cancer and phase I studies for chemotherapies, antisense and targeted therapies. Most of her recent work was focused on tumor perfusion modifiers such as antivascular agents. Dr. Borghi obtained her medical degree from the University of Cordoba School of Medicine in March 1984 and the French equivalent in 1994 from the University of Paris V.

“The appointment of such an experienced clinical manager and scientific researcher as Dr. Borghi is a very significant milestone for Nanobiotix,” said Laurent Levy, Ph.D., chief executive officer of Nanobiotix. “With strong preclinical work behind us, we are looking forward to the next giant step for Nanobiotix, our first-in-man and the start of clinical trials in the not-too-distant future. We therefore expect to benefit from Dr. Borghi’s substantial accomplishments related to turning promising research into approved products designed to produce favorable outcomes for patients.”


Nanobiotix is an emerging nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop nanoXray™ - a technology platform that is expected to be turned ‘on’ and ‘off’ outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is intended to resolve radiation therapy’s biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of x-ray is necessary. The core of a nanoXray nanoparticle is an inactive and inert substance—not a drug—that can subsequently be activated in order to locally (intratumor) increase the dose of x-ray, which is then expected to lead to higher efficiency. After nanoXray nanoparticles accumulate in the target tissues, a standard x-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.

Source: Nanobiotix

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.